Sanofi's Dupixent Drug Meets Endpoints for Atopic Dermatitis Treatment
16 Mayo 2018 - 01:03AM
Noticias Dow Jones
By Marc Navarro Gonzalez
Sanofi SA (SAN.FR) said Wednesday that a phase 3 trial
evaluating its drug Dupixent to treat moderate to severe atopic
dermatits in adolescents met its primary and key secondary
endpoints.
The French drug maker said the trial showed treatment with
Dupixent as monotherapy "significantly improved measure of overall
disease severity, skin clearing, itching and certain health-related
quality of life measures."
Patients treated with Dupixent had significant improvement in
disease severity at 16 weeks, Sanofi said.
In 2016, the U.S. Food and Drug Administration granted
Breakthrough Therapy designation for Dupixent for the treatment of
moderate-to-severe atopic dermatitis in adolescents between 12 and
17 years old, and for the treatment of severe cases of the disease
in children between six months and 11 years of age.
Write to Marc Navarro Gonzalez at marc.navarro@dowjones.com
(END) Dow Jones Newswires
May 16, 2018 01:48 ET (05:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024